Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endorectal multiparametric 3-tesla magnetic resonance imaging associated with systematic cognitive biopsies does not increase prostate cancer detection rate: a randomized prospective trial.
Taverna G, Bozzini G, Grizzi F, Seveso M, Mandressi A, Balzarini L, Mrakic F, Bono P, De Franceco O, Buffi N, Lughezzani G, Lazzeri M, Casale P, Guazzoni GF. Taverna G, et al. Among authors: balzarini l. World J Urol. 2016 Jun;34(6):797-803. doi: 10.1007/s00345-015-1711-4. Epub 2015 Oct 19. World J Urol. 2016. PMID: 26481226 Clinical Trial.
68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study.
Lopci E, Saita A, Lazzeri M, Lughezzani G, Colombo P, Buffi NM, Hurle R, Marzo K, Peschechera R, Benetti A, Zandegiacomo S, Pasini L, Lista G, Cardone P, Castello A, Maffei D, Balzarini L, Chiti A, Guazzoni G, Casale P. Lopci E, et al. Among authors: balzarini l. J Urol. 2018 Jul;200(1):95-103. doi: 10.1016/j.juro.2018.01.079. Epub 2018 Feb 1. J Urol. 2018. PMID: 29409824
Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis.
Lopci E, Lughezzani G, Castello A, Saita A, Colombo P, Hurle R, Peschechera R, Benetti A, Zandegiacomo S, Pasini L, Casale P, Pietro D, Bevilacqua G, Balzarini L, Buffi NM, Guazzoni G, Lazzeri M. Lopci E, et al. Among authors: balzarini l. Eur Urol Focus. 2021 Jul;7(4):764-771. doi: 10.1016/j.euf.2020.03.004. Epub 2020 Apr 17. Eur Urol Focus. 2021. PMID: 32312701
The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M, Stabile A, Lughezzani G, Pepe P, Galosi AB, Naselli A, Naspro R, Nicolai M, La Croce G, Aljoulani M, Perugini G, Guazzoni G, Montorsi F, Balzarini L, Sironi S, Da Pozzo LF. Roscigno M, et al. Among authors: balzarini l. Clin Genitourin Cancer. 2020 Dec;18(6):e698-e704. doi: 10.1016/j.clgc.2020.04.006. Epub 2020 May 4. Clin Genitourin Cancer. 2020. PMID: 32493676
Targeted 11C-choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy.
Lazzeri M, Lopci E, Lughezzani G, Colombo P, Casale P, Hurle R, Saita A, Leonardi L, Lista G, Peschechera R, Pasini L, Rodari M, Zandegiacomo S, Benetti A, Cardone P, Mrakic F, Balzarini L, Chiti A, Guazzoni G, Buffi NM. Lazzeri M, et al. Among authors: balzarini l. Eur J Hybrid Imaging. 2017;1(1):9. doi: 10.1186/s41824-017-0011-1. Epub 2017 Nov 1. Eur J Hybrid Imaging. 2017. PMID: 29782590 Free PMC article.
Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy, Italy.
Lazzeri M, Duga S, Azzolini E, Fasulo V, Buffi N, Saita A, Lughezzani G, Paraboschi EM, Hurle R, Nobili A, Cecconi M, Guazzoni G, Casale P, Asselta R; Humanitas COVID-19 Task Force, The Humanitas Gavazzeni COVID-19 Task Force. Lazzeri M, et al. Minerva Urol Nephrol. 2022 Feb;74(1):77-84. doi: 10.23736/S2724-6051.20.04081-3. Epub 2021 Jan 13. Minerva Urol Nephrol. 2022. PMID: 33439572 Free article.
Multiparametric magnetic resonance imaging and clinical variables: Which is the best combination to predict reclassification in active surveillance patients?
Roscigno M, Stabile A, Lughezzani G, Pepe P, Dell'Atti L, Naselli A, Naspro R, Nicolai M, La Croce G, Muhannad A, Perugini G, Guazzoni G, Montorsi F, Balzarini L, Sironi S, Da Pozzo LF. Roscigno M, et al. Among authors: balzarini l. Prostate Int. 2020 Dec;8(4):167-172. doi: 10.1016/j.prnil.2020.05.003. Epub 2020 May 28. Prostate Int. 2020. PMID: 33425794 Free PMC article.
How I faced my prostate cancer: a molecular biologist's perspective.
Zuradelli M, Lazzeri M, Lopci E, Zucali PA, Balzarini L, Guazzoni G, Colombo P, Scorsetti M, Franzese C, Asselta R, Soldà G, Duga S. Zuradelli M, et al. Among authors: balzarini l. NPJ Precis Oncol. 2021 Sep 24;5(1):88. doi: 10.1038/s41698-021-00229-5. NPJ Precis Oncol. 2021. PMID: 34561542 Free PMC article.
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease.
Fiorino G, Bonifacio C, Peyrin-Biroulet L, Minuti F, Repici A, Spinelli A, Fries W, Balzarini L, Montorsi M, Malesci A, Danese S. Fiorino G, et al. Among authors: balzarini l. Inflamm Bowel Dis. 2011 May;17(5):1073-80. doi: 10.1002/ibd.21533. Epub 2010 Nov 8. Inflamm Bowel Dis. 2011. PMID: 21484958 Clinical Trial.
137 results